Targeting Metastatic Cancer: Disseminated Tumor Cells and Premetastatic Niches
Abstract
BACKGROUND: Metastases are simply known as cancers spread to another part of the body, and often be responsible for the severity of cancer prognosis. Somehow, the complex mechanisms of metastases are not fully understood yet.
CONTENT: The characteristic of cancer is akin to a never-healing wound. Cancer cells are plastic and dynamic as they build their niches and developed into metastases, even when they seem dormant. Therefore, cancer cells can survive the immune system. Recent research has shown the distinct biology of metastasis-initiating cell, which leads to tumor development in distant organs, immune surveillance evasion, and co-option of metastatic micro-environments. Effective cancer therapies must consider the regenerative states of metastatic malignancies and have careful observation of patient phenotypes.
SUMMARY: This review aimed to provide an insight on genesis and characteristics of metastases, starting from its seeding and dormancy, until the advance phase. Thus, developing therapy for cancer metastases should not start as it grows, but even as earlier strategies since the primary tumor was detected.
KEYWORDS: cancer metastasis, DTC, CTC, CSC, dormancy, pre-metastatic niche, plasticity
Full Text:
PDFReferences
Turajlic S, Swanton C. Metastasis as an evolutionary process. Science. 2016; 352(6282): 169-75, CrossRef.
Meiliana A, Dewi NM, Wijaya A. Cancer Genetics and Epigenetics in Cancer Risk Assessment. Mol Cell Biomed Sci. 2021; 5(2): 41-61, CrossRef.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646-74, CrossRef.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1): 57-70, CrossRef.
Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017; 168(4): 670-91, CrossRef.
Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016; 529(7586): 298-306, CrossRef.
Hu Z, Curtis C. Looking backward in time to define the chronology of metastasis. Nat Commun. 2020; 11(1): 3213, CrossRef.
Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2(8): 563-72, CrossRef.
Meiliana A, Dewi NM, Wijaya A. The Immunobiology of Cancer: An Update Review. Indones Biomed J. 2017; 9(2): 53-72, CrossRef.
Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009; 9(4): 302-12, CrossRef.
Celià-Terrassa T, Kang Y. Metastatic niche functions and therapeutic opportunities. Nat Cell Biol. 2018; 20(8): 868-77, CrossRef.
Garner H, de Visser KE. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol. 2020; 20(8): 483-97, CrossRef.
Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PloS One. 2015; 10(3): e0119312, CrossRef.
Park J, Wysocki RW, Amoozgar Z, Maiorino L, Fein MR, Jorns J, et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med. 2016; 8(361): 361ra138, CrossRef.
Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz JK, Denkert C, et al. The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2015; 6(1): 570-83, CrossRef.
Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009; 9(4): 274-84, CrossRef.
Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 2007; 446(7137): 765-70, CrossRef.
Padua D, Zhang XHF, Wang Q, Nadal C, Gerald WL, Gomis RR, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008; 133(1): 66-77, CrossRef.
Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest. 2005; 115(1): 44-55, CrossRef.
Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011; 11(6): 411-25, CrossRef.
Ikawati M, Ertanto Y, Endah ES, Pudjiraharti S, Meiyanto E, Jenie RI. Anti-osteoporosis potencies of Zingiber officinale Rosc. rhizome water extract and DFA III produced from Dahlia spp. L.: in vivo and in vitro studies. Indones Biomed J. 2022; 14(1): 104-15, CrossRef.
Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011; 8(6): 344-56, CrossRef.
Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006; 7(1): 41-53, CrossRef.
Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014; 25(4): 501-15, CrossRef.
Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordón-Cardo C, et al. Identifying site-specific metastasis genes and functions. Cold Spring Harb Symp Quant Biol. 2005; 70: 149-58, CrossRef.
Disibio G, French SW. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008; 132(6): 931-9, CrossRef.
Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin N Am. 2005; 18(1): 75-84, CrossRef.
Lugassy C, Kleinman HK, Vermeulen PB, Barnhill RL. Angiotropism, pericytic mimicry and extravascular migratory metastasis: an embryogenesis-derived program of tumor spread. Angiogenesis. 2020; 23(1): 27-41, CrossRef.
Kuol N, Stojanovska L, Apostolopoulos V, Nurgali K. Role of the nervous system in cancer metastasis. J Exp Clin Cancer Res CR. 2018; 37(1): 5, CrossRef.
Gkountela S, Castro-Giner F, Szczerba BM, Vetter M, Landin J, Scherrer R, et al. Circulating tumor cell clustering shapes dna methylation to enable metastasis seeding. Cell. 2019; 176(1-2): 98-112.e14, CrossRef.
Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol Off J Am Soc Clin Oncol. 2000; 18(1): 80-6, CrossRef.
Tabassum DP, Polyak K. Tumorigenesis: it takes a village. Nat Rev Cancer. 2015; 15(8): 473-83, CrossRef.
Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5): 1110-22, CrossRef.
Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011; 20(5): 576-90, CrossRef.
Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, et al. Antioxidants can increase melanoma metastasis in mice. Sci Transl Med. 2015; 7(308): 308re8, CrossRef.
Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015; 527(7577): 186-91, CrossRef.
Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004; 4(6): 448-56, CrossRef.
Bednarz-Knoll N, Alix-Panabières C, Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res. 2011; 13(6): 228, CrossRef.
Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Crit Rev Oncol Hematol. 2019; 134: 39-45, CrossRef.
Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2016; 35(10): 1216-24, CrossRef.
Ganesh K, Massagué J. Targeting metastatic cancer. Nat Med. 2021; 27(1): 34-44, CrossRef.
Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, et al. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat Med. 2019; 25(10): 1534-9, CrossRef.
Alix-Panabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2012; 63: 199-215, CrossRef.
Pantel K, Hille C, Scher HI. Circulating tumor cells in prostate cancer: from discovery to clinical utility. Clin Chem. 2019; 65(1): 87-99, CrossRef.
Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010; 464(7291): 999-1005, CrossRef.
Jones S, Chen W dong, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci. 2008; 105(11): 4283-8, CrossRef.
Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013; 73(10): 2965-75, CrossRef.
LeBleu VS, O’Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014; 16(10): 992-1003, CrossRef.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859): 105-11, CrossRef.
Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017; 23(10): 1124-34, CrossRef.
Shimokawa M, Ohta Y, Nishikori S, Matano M, Takano A, Fujii M, et al. Visualization and targeting of LGR5+ human colon cancer stem cells. Nature. 2017; 545(7653): 187-92, CrossRef.
Rahmawati DY, Dwifulqi H, Sandra F. Origin, Stemness, Marker and Signaling Pathway of Oral Cancer Stem Cell. Mol Cell Biomed Sci. 2020; 4(3): 100-4, CrossRef.
Sandra F, Sudiono J, Sidharta EA, Sunata EP, Sungkono DJ, Dirgantara Y, et al. Conditioned media of human umbilical cord blood mesenchymal stem cell-derived secretome induced apoptosis and inhibited growth of HeLa cells. Indones Biomed J. 2014; 6(1): 57-62, CrossRef.
Nadia YF, Syahrani RA, Arumsari S, Sadikin M, Wanandi SI. Effect of cell culture medium on the proliferation and stemness of CD24-/CD44+ human breast cancer stem cells. Indones Biomed J. 2021; 13(4): 355-63, CrossRef.
Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015; 21(8): 846-53, CrossRef.
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013; 339(6127): 1546-58, CrossRef.
Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013; 153(1): 17-37, CrossRef.
Esteller M. Epigenetics in cancer. N Engl J Med. 2008; 358(11): 1148-59, CrossRef.
Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1): 12-27, CrossRef.
Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJA. The origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer. 2005; 5(11): 899-904, CrossRef.
Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Migrating cancer stem cells — an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005; 5(9): 744-9, CrossRef.
Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea—a paradigm shift. Cancer Res. 2006; 66(4): 1883-90, CrossRef.
Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9(4): 265-73, CrossRef.
Medema JP. Cancer stem cells: The challenges ahead. Nat Cell Biol. 2013; 15(4): 338-44, CrossRef.
Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009; 28(1): 15-33, CrossRef.
Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT, and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012; 72(7): 1878-89, CrossRef.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4): 704-15, CrossRef.
Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34): 4741-51, CrossRef.
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13(10): 714-26, CrossRef.
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013; 31(6): 539-44, CrossRef.
Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1α promotes metastasis. Nat Cell Biol. 2008; 10(3): 295-305, CrossRef.
Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 2015; 526(7571): 131-5, CrossRef.
Del Pozo Martin Y, Park D, Ramachandran A, Ombrato L, Calvo F, Chakravarty P, et al. Mesenchymal cancer cell-stroma crosstalk promotes niche activation, epithelial reversion, and metastatic colonization. Cell Rep. 2015; 13(11): 2456-69, CrossRef.
Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017; 14(10): 611-29, CrossRef.
Chen BJ, Wu JS, Tang YJ, Tang YL, Liang XH. What makes leader cells arise: Intrinsic properties and support from neighboring cells. J Cell Physiol. 2020; 235(12): 8983-95, CrossRef.
Vilchez Mercedes SA, Bocci F, Levine H, Onuchic JN, Jolly MK, Wong PK. Decoding leader cells in collective cancer invasion. Nat Rev Cancer. 2021; 21(9): 592-604, CrossRef.
Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020; 11(1): 5120, CrossRef.
van Helvert S, Storm C, Friedl P. Mechanoreciprocity in cell migration. Nat Cell Biol. 2018; 20(1): 8-20, CrossRef.
Bocci F, Levine H, Onuchic JN, Jolly MK. Deciphering the dynamics of epithelial-mesenchymal transition and cancer stem cells in tumor progression. Curr Stem Cell Rep. 2019; 5(1): 11-21, CrossRef.
Cheung KJ, Gabrielson E, Werb Z, Ewald AJ. Collective invasion in breast cancer requires a conserved basal epithelial program. Cell. 2013; 155(7): 1639-51, CrossRef.
desJardins-Park HE, Foster DS, Longaker MT. Fibroblasts and wound healing: an update. Regen Med. 2018; 13(5): 491-5, CrossRef.
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020; 20(3): 174-86, CrossRef.
Saénz-de-Santa-María I, Celada L, Chiara MD. The leader position of mesenchymal cells expressing n-cadherin in the collective migration of epithelial cancer. Cells. 2020; 9(3): 731, CrossRef.
Richardson AM, Havel LS, Koyen AE, Konen JM, Shupe J, Wiles WG, et al. Vimentin is required for lung adenocarcinoma metastasis via heterotypic tumor cell-cancer-associated fibroblast interactions during collective invasion. Clin Cancer Res Off J Am Assoc Cancer Res. 2018; 24(2): 420-32, CrossRef.
Abdollah NA, Safiai NIM, Ahmad MK, Das KT, Razak SRA. Suppression of MiR130a-3p using CRISPR/Cas9 induces proliferation and migration of non-small cell lung cancer cell line. Indones Biomed J. 2021; 13(4): 364-74, CrossRef.
Labernadie A, Kato T, Brugués A, Serra-Picamal X, Derzsi S, Arwert E, et al. A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nat Cell Biol. 2017; 19(3): 224-37, CrossRef.
Theret M, Mounier R, Rossi F. The origins and non-canonical functions of macrophages in development and regeneration. Development. 2019; 146(9): dev156000, CrossRef.
Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006; 124(2): 263-6, CrossRef.
Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X. Tumor-associated macrophages: recent insights and therapies. Front Oncol. 2020; 10: 188, CrossRef.
Pandya P, Orgaz JL, Sanz-Moreno V. Actomyosin contractility and collective migration: may the force be with you. Curr Opin Cell Biol. 2017; 48: 87-96, CrossRef.
Khalil AA, de Rooij J. Cadherin mechanotransduction in leader-follower cell specification during collective migration. Exp Cell Res. 2019; 376(1): 86-91, CrossRef.
Quan Q, Wang X, Lu C, Ma W, Wang Y, Xia G, et al. Cancer stem-like cells with hybrid epithelial/mesenchymal phenotype leading the collective invasion. Cancer Sci. 2020; 111(2): 467-76, CrossRef.
Yang C, Cao M, Liu Y, He Y, Du Y, Zhang G, et al. Inducible formation of leader cells driven by CD44 switching gives rise to collective invasion and metastases in luminal breast carcinomas. Oncogene. 2019; 38(46): 7113-32, CrossRef.
Friberg S, Nyström A. Cancer metastases: early dissemination and late recurrences. Cancer Growth Metastasis. 2015; 8: 43-9. Friberg S, Nyström A. Cancer metastases: early dissemination and late recurrences. Cancer Growth Metastasis. 2015; 8: 43-9, CrossRef.
Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 2001; 12(4): 863-79, CrossRef.
Ghiso JAA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol. 1999; 147(1): 89-104, CrossRef.
Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VHC, Groom AC, et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat. 2003; 82(3): 199-206, CrossRef.
Aguirre-Ghiso JA, Sosa MS. Emerging topics on disseminated cancer cell dormancy and the paradigm of metastasis. Annu Rev Cancer Biol. 2018; 2(1): 377-93, CrossRef.
Willis RA. The Spread of Tumours in the Human Body. London: J. & A. Churchill; 1934, NLMID.
Hadfield G. The dormant cancer cell. Br Med J. 1954; 2(4888): 607-10,
Townson JL, Chambers AF. Dormancy of solitary metastatic cells. Cell Cycle. 2006; 5(16): 1744-50, CrossRef.
Vallette FM, Olivier C, Lézot F, Oliver L, Cochonneau D, Lalier L, et al. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer. Biochem Pharmacol. 2019; 162: 169-76, CrossRef.
Aguirre-Ghiso JA. How dormant cancer persists and reawakens. Science. 2018; 361(6409): 1314-5, CrossRef.
Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell. 2016; 165(1): 45-60, CrossRef.
Pommier A, Anaparthy N, Memos N, Kelley ZL, Gouronnec A, Yan R, et al. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 2018; 360(6394): eaao4908, CrossRef.
Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11): 834-4, CrossRef.
Sosa MS, Bernstein E, Aguirre-Ghiso JA. Epigenetic regulation of cancer dormancy as a plasticity mechanism for metastasis initiation. In: Wang Y, Crea F, editors. Tumor Dormancy and Recurrence. Cham: Springer International Publishing; 2017. p. 1-16, CrossRef.
Risson E, Nobre AR, Maguer-Satta V, Aguirre-Ghiso JA. The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer. 2020; 1(7): 672-80, CrossRef.
Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase–like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 2006; 66(3): 1702-11, CrossRef.
Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015; 5(9): 915-9, CrossRef.
Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020; 20(7): 398-411, CrossRef.
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382): 1350-5, CrossRef.
Glickman MS, Sawyers CL. Converting cancer therapies into cures: lessons from infectious diseases. Cell. 2012; 148(6): 1089-98, CrossRef.
Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194(4260): 23-8, CrossRef.
Sansregret L, Vanhaesebroeck B, Swanton C. Determinants and clinical implications of chromosomal instability in cancer. Nat Rev Clin Oncol. 2018; 15(3): 139-50, CrossRef.
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017; 168(4): 707-23, CrossRef.
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23): 2189-99, CrossRef.
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230): 124-8, CrossRef.
Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016; 375(9): 819-29, CrossRef.
Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, et al. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014; 32(34): 3848-57, CrossRef.
Burnet FM. The concept of immunological surveillance. Immunol Asp Neoplasia. 1970; 13: 1–27, CrossRef.
Corthay A. Does the immune system naturally protect against cancer? Front Immunol. 2014; 5: 197, CrossRef.
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22: 329-60, CrossRef.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11): 991-8, CrossRef.
Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA. 2000; 97(26): 14608-13, CrossRef.
Salgia R, Kulkarni P. The genetic/non-genetic duality of drug “resistance” in cancer. Trends Cancer. 2018; 4(2): 110-8, CrossRef.
Luskin MR, Murakami MA, Manalis SR, Weinstock DM. Targeting minimal residual disease: a path to cure? Nat Rev Cancer. 2018; 18(4): 255-63, CrossRef.
Ramirez M, Rajaram S, Steininger RJ, Osipchuk D, Roth MA, Morinishi LS, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun. 2016; 7: 10690, CrossRef.
Tata PR, Rajagopal J. Cellular plasticity: 1712 to the present day. Curr Opin Cell Biol. 2016; 43: 46-54, CrossRef.
Sipos F, Constantinovits M, Műzes G. Intratumoral functional heterogeneity and chemotherapy. World J Gastroenterol. 2014; 20(10): 2429-32, CrossRef.
Zellmer VR, Zhang S. Evolving concepts of tumor heterogeneity. Cell Biosci. 2014; 4: 69, CrossRef.
Lim JS, Ibaseta A, Fischer MM, Cancilla B, O’Young G, Cristea S, et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature. 2017; 545(7654): 360-4, CrossRef.
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, et al. Toward minimal residual disease-directed therapy in melanoma. Cell. 2018; 174(4): 843-855.e19, CrossRef.
Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3(75): 75ra26, CrossRef.
Yano S, Nakataki E, Ohtsuka S, Inayama M, Tomimoto H, Edakuni N, et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res. 2005; 15(2): 107-11, CrossRef.
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019; 20(2): 69-84, CrossRef.
Weng CH, Chen LY, Lin YC, Shih JY, Lin YC, Tseng RY, et al. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene. 2019; 38(4): 455-68, CrossRef.
Chung JH, Rho JK, Xu X, Lee JS, Yoon HI, Lee CT, et al. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer Amst Neth. 2011; 73(2): 176-82, CrossRef.
Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2020; 19(1): 39-56, CrossRef.
Reyngold M, Turcan S, Giri D, Kannan K, Walsh LA, Viale A, et al. Remodeling of the methylation landscape in breast cancer metastasis. PloS One. 2014; 9(8): e103896, CrossRef.
Biehs B, Dijkgraaf GJP, Piskol R, Alicke B, Boumahdi S, Peale F, et al. A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition. Nature. 2018; 562(7727): 429-33, CrossRef.
Sánchez-Danés A, Larsimont JC, Liagre M, Muñoz-Couselo E, Lapouge G, Brisebarre A, et al. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. Nature. 2018; 562(7727): 434-8, CrossRef.
Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018; 33(5): 890-904.e5, CrossRef.
Fallahi-Sichani M, Becker V, Izar B, Baker GJ, Lin JR, Boswell SA, et al. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. Mol Syst Biol. 2017; 13(1): 905, CrossRef.
Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012; 490(7420): 412-6, CrossRef.
Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2019; 14(10): 1784-93, CrossRef.
Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol Off J Am Soc Clin Oncol. 2017; 35(26): 3065-74, CrossRef.
Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol Off J Am Soc Clin Oncol. 2018; 36(24): 2492-503, CrossRef.
Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015; 6: 6377, CrossRef.
Lim ST, Chen XL, Lim Y, Hanson DA, Vo TT, Howerton K, et al. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell. 2008; 29(1): 9-22, CrossRef.
Gastaldi S, Sassi F, Accornero P, Torti D, Galimi F, Migliardi G, et al. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene. 2013; 32(11): 1428-40, CrossRef.
Chiche A, Di-Cicco A, Sesma-Sanz L, Bresson L, de la Grange P, Glukhova MA, et al. p53 controls the plasticity of mammary luminal progenitor cells downstream of Met signaling. Breast Cancer Res BCR. 2019; 21(1): 13, CrossRef.
Quintanal-Villalonga Á, Chan JM, Yu HA, Pe’er D, Sawyers CL, Sen T, et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020; 17(6): 360-71, CrossRef.
Cicatiello V, Apicella I, Tudisco L, Tarallo V, Formisano L, Sandomenico A, et al. Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models. Oncotarget. 2015; 6(12): 10563-76, CrossRef.
Hanahan D. Rethinking the war on cancer. Lancet Lond Engl. 2014; 383(9916): 558-63, CrossRef.
Oskarsson T, Batlle E, Massagué J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014; 14(3): 306-21, CrossRef.
Ombrato L, Nolan E, Kurelac I, Mavousian A, Bridgeman VL, Heinze I, et al. Metastatic-niche labelling reveals parenchymal cells with stem features. Nature. 2019; 572(7771): 603-8, CrossRef.
Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017; 17(5): 302-17, CrossRef.
Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005; 438(7069): 820-7. https://doi.org/10.1038/nature04186">CrossRef.
Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9(4): 239-52, CrossRef.
Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009; 9(4): 285-93, CrossRef.
Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature. 2015; 528(7582): 413-7, CrossRef.
Cox TR, Bird D, Baker AM, Barker HE, Ho MWY, Lang G, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res. 2013; 73(6): 1721-32, CrossRef.
Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015; 522(7554): 106-10, CrossRef.
Zhang W, Zhang C, Li W, Deng J, Herrmann A, Priceman SJ, et al. CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation. Eur J Immunol. 2015; 45(1): 71-81, CrossRef.
Deng J, Liu Y, Lee H, Herrmann A, Zhang W, Zhang C, et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell. 2012; 21(5): 642-54, CrossRef.
Pal SK, Pham A, Vuong W, Liu X, Lin Y, Ruel N, et al. Prognostic significance of neutrophilic infiltration in benign lymph nodes in patients with muscle-invasive bladder cancer. Eur Urol Focus. 2017; 3(1): 130-5, CrossRef.
Cicatiello V, Apicella I, Tudisco L, Tarallo V, Formisano L, Sandomenico A, et al. Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models. Oncotarget. 2015; 6(12): 10563-76, CrossRef.
Wakisaka N, Hasegawa Y, Yoshimoto S, Miura K, Shiotani A, Yokoyama J, et al. Primary tumor-secreted lymphangiogenic factors induce pre-metastatic lymphvascular niche formation at sentinel lymph nodes in oral squamous cell carcinoma. PloS One. 2015; 10(12): e014405, CrossRef.
Torrano V, Royo F, Peinado H, Loizaga-Iriarte A, Unda M, Falcón-Perez JM, et al. Vesicle-MaNiA: extracellular vesicles in liquid biopsy and cancer. Curr Opin Pharmacol. 2016; 29: 47-53, CrossRef.
Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn JMD. 2015; 17(3): 209-24, CrossRef.
Sleeman JP. The metastatic niche and stromal progression. Cancer Metastasis Rev. 2012; 31(3): 429-40, CrossRef.
Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015; 527(7578): 329-35, CrossRef.
Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011; 121(4): 1298-312, CrossRef.
Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XHF, Lee DJ, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014; 156(5): 1002-16, CrossRef.
Price TT, Burness ML, Sivan A, Warner MJ, Cheng R, Lee CH, et al. Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. Sci Transl Med. 2016; 8(340): 340ra73, CrossRef.
Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013; 15(7): 807-17, CrossRef.
Correa D, Somoza RA, Lin P, Schiemann WP, Caplan AI. Mesenchymal stem cells regulate melanoma cancer cells extravasation to bone and liver at their perivascular niche. Int J Cancer. 2016; 138(2): 417-27, CrossRef.
Hiratsuka S, Goel S, Kamoun WS, Maru Y, Fukumura D, Duda DG, et al. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proc Natl Acad Sci USA. 2011; 108(9): 3725-30, CrossRef.
Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18(6): 883-91, CrossRef.
Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410(6824): 50-6, CrossRef.
Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong STC, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015; 527(7579): 472-6, CrossRef.
Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015; 527(7579): 525-30, CrossRef.
Celià-Terrassa T, Kang Y. Distinctive properties of metastasis-initiating cells. Genes Dev. 2016; 30(8): 892-908, CrossRef.
Nieto MA, Huang RYJ, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016; 166(1): 21-45, CrossRef.
Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016; 533(7604): 493-8, CrossRef.
Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018; 24(7): 1024-35, CrossRef.
Smith HA, Kang Y. Determinants of organotropic metastasis. Annu Rev Cancer Biol. 2017; 1(1): 403-23, CrossRef.
Zheng H, Bae Y, Kasimir-Bauer S, Tang R, Chen J, Ren G, et al. Therapeutic antibody targeting tumor- and osteoblastic niche-derived jagged1 sensitizes bone metastasis to chemotherapy. Cancer Cell. 2017; 32(6): 731-747.e6, CrossRef.
Wu JB, Yin L, Shi C, Li Q, Duan P, Huang JM, et al. MAOA-dependent activation of shh-il6-rankl signaling network promotes prostate cancer metastasis by engaging tumor-stromal cell interactions. Cancer Cell. 2017; 31(3): 368-82, CrossRef.
Fontebasso Y, Dubinett SM. Drug development for metastasis prevention. Crit Rev Oncog. 2015; 20(5-6): 449-73, CrossRef.
Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019; 575(7782): 299-309, CrossRef.
DOI: https://doi.org/10.18585/inabj.v14i4.2035
Copyright (c) 2022 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
